Background Among the many consequences of loss of CFTR protein function, a significant reduction of the secretion of bicarbonate (HCO 3 − ) in cystic fibrosis (CF) is a major pathogenic feature. Loss of HCO 3 − leads to abnormally low pH and impaired mucus clearance in airways and other exocrine organs, which suggests that NaHCO 3 inhalation may be a low-cost, easily accessible therapy for CF. Objective To evaluate the safety, tolerability, and effects of inhaled aerosols of NaHCO 3 solutions (4.2% and 8.4%). Methods An experimental, prospective, open-label, pilot, clinical study was conducted with 12 CF volunteer participants over 18 years of age with bronchiectasis and pulmonary functions classified as mildly to severely depressed. Sputum rheology, pH, and microbiology were examined as well as spirometry, exercise performance, quality-of-life assessments, dyspnea, blood count, and venous blood gas levels. Results Sputum pH increased immediately after inhalation of NaHCO 3 at each clinical visit and was inversely correlated with rheology when all parameters were evaluated: [G′ (elasticity of the mucus) = − 0.241; G″ (viscosity of the mucus) = − 0.287; G* (viscoelasticity of the mucus) = − 0.275]. G* and G′ were slightly correlated with peak flow, forced expiratory volume in 1 s (FEV 1 ), and quality of life; G″ was correlated with quality of life; sputum pH was correlated with oxygen consumption (VO 2 ) and vitality score in quality of life. No changes were observed in blood count, venous blood gas, respiratory rate, heart rate, peripheral oxygen saturation of hemoglobin (SpO 2 ), body temperature, or incidence of dyspnea. No adverse events associated with the study were observed. Conclusion Nebulized NaHCO 3 inhalation appears to be a safe and well tolerated potential therapeutic agent in the management of CF. Nebulized NaHCO 3 inhalation temporarily elevates airway liquid pH and reduces sputum viscosity and viscoelasticity.
Introduction
In recent years knowledge regarding the pathophysiology of pulmonary disease in cystic fibrosis (CF; OMIM: #219700) has expanded significantly from studies on ion transport by epithelial anion channels in affected tissues [1, 2] . The early literature reported that viscous, thick mucus with high concentrations of solids that obstructed the airways in CF was mainly caused by dehydration of airway surface liquid (ASL) due to dysfunction in chloride transport by the CFTR (cystic fibrosis transmembrane conductance regulator) protein and presumably concomitant sodium/water hyperabsorption from airway luminal fluid [3] , which was thought to provide a hypoxic environment favoring bacterial growth [4] . However, recent studies found that defects in the CFTR protein also reduced transport of bicarbonate (HCO 3 − ), which is essential for developing and maintaining the physiological properties of mucins [5, 6] . Mucins create a gel matrix to lubricate epithelial surfaces and act as a barrier against pathogens [7] . Reduction or absence of HCO 3 − prevents normal expansion and maturation of mucins since HCO 3 − must be physiologically secreted with mucin exocytosis to capture calcium (Ca 2+ ) and buffer free hydrogen (H + ) [8] [9] [10] . Reduced HCO 3 − may also favor growth of bacteria, increased viscous mucus production and biofilm formation, and depressed immune responses consequent to reduced pH of the ASL [11] [12] [13] .
In CF, besides the direct effects of low levels of HCO 3 − on the viscoelastic properties of mucus, other factors such as increased elastase, DNA nets, and oxygen free radicals from neutrophil apoptosis are released in the airways [7] as a consequence of inflammation and infection, which furthers deterioration of lung function, the primary cause of morbidity and mortality in CF [14] .
Only relatively recently were the abnormalities of mucociliary transport in CF suggested to be caused by a HCO 3 − deficiency in ASL [8] . In vitro, NaHCO 3 was shown to change the rheological properties of sputum [15] . Thus, in CF, three factors seem to justify the therapeutic use of inhaled HCO 3 − aerosol: (1) HCO 3 − is critical in the extracellular processing of mucus to attain physiologically rheological properties [5, 8, 10, 11, 16] ; (2) increased ASL pH decreases bacterial proliferation [13] ; (3) hyperosmotic solutions of NaHCO 3 should help mobilize and remove airway surface debris [17, 18] .
In this context, the objective of this study was to evaluate the safety and tolerability of inhaling aerosolized NaHCO 3 as the primary outcome in light of its potential effect on clinical and laboratory markers in CF as secondary outcomes.
Method
This study was a phase I longitudinal non-randomized, unblinded clinical study of inhaled aerosolized NaHCO 3 with dose escalation in volunteer CF participants performed at a single site. The study determined safety and tolerability and assessed clinical and laboratory markers following a modified PICOT strategy:
(P) Population: CF patients over 10 years of age with two sweat tests with a sweat chloride concentration ≥ 60 meq/L and/or two pathogenic variants in the CFTR gene (OMIM: #602421). Twelve of 19 volunteers with CF (nine females) over 18 years of age were included and followed upto completion of the protocol. In addition, nine pancreatic insufficient (PI) patients were included. All subjects were diagnosed with bronchiectasis from computer-assisted tomography (CAT) images of the thorax, with pulmonary functions, including forced expiratory volume in 1 s (FEV 1 ) reductions, assessed as mild to severe. Participants included in this study were clinically stable, on continuous use of oral and/or inhaled antibiotics, and were able to expectorate spontaneously (Table 1) .
(I) Intervention: Serial doses of 5 mL of 4.2% or 8.4% NaHCO 3 dissolved in distilled water were inhaled as an aerosol mist.
(C) Control: Temporal analysis in the same individual relative to NaHCO 3 administration. There was no placebo, active drug, or healthy subjects that served as a control arm.
(O) Outcomes: The primary outcome was safety and tolerability of inhaling aerosolized NaHCO 3 . In addition, the following parameters were evaluated as secondary outcomes: physical/chemical characteristics of sputum, pulmonary function, Harvard step-test performance, sputum microbiology, serum electrolytes, blood count, and questionnaire scores for assessing quality of life and dyspnea.
(T) Time: Ten weeks. Study parameters were assessed and recorded after weekly visits during the 10-week study protocol.
The project (#12398956) was approved by the research ethics committee of the Faculdade de Ciências Médicas, Universidade Estadual de Campinas. Informed consent was obtained from each participant.
Intervention Model
In the study, each participant underwent a screening visit (1) to establish pre-intervention values of parameters to be assessed for effects during and post-intervention, and (2) to train for NaHCO 3 inhalation and receive a supply of 5-mL doses of 4.2% or 8.4% NaHCO 3 solution for home inhalation according to the following protocol, which was comprised of five treatment regimens in the following sequence: (1) 4.2% (once a day) for 2 weeks;
(2) 4.2% (twice daily) for 2 weeks; (3) 8.4% (once a day) for 2 weeks; (4) 8.4% (twice daily) for 2 weeks; (5) no NaHCO 3 for 2 weeks (wash-out period). Each patient was evaluated clinically during the initial screening visit and during each visit after each dose regimen. CF participants did not use inhaled hypertonic saline during the intervention, but four patients continued the use of inhaled dornase alpha. Inhalation of hypertonic saline was avoided because it is used therapeutically to enhance sputum production. Even though the mechanisms of action of hypertonic saline and NaHCO 3 inhalation are not the same, the concomitant use of both drugs would inherently complicate the evaluation of the effects of NaHCO 3 . No alteration or interruption of the participants' usual treatments occurred as a result of the use of NaHCO 3 inhalation during the intervention period. However, bicarbonate inhalation was scheduled to be the first inhalation treatment of the day, and the participants were advised to delay performing respiratory physiotherapy immediately after the bicarbonate inhalation in order to delay any effects on immediately clearing the drug and to avoid the impact of respiratory physiotherapy on clearance of airway secretions; both factors would complicate the interpretation of effects of NaHCO 3 inhalation.
The order of the aerosol solutions was not evaluated. Additionally, participants taking inhaled antibiotics at the beginning of the study were advised to continue their prescribed use so as to avoid introducing an extraneous variable affecting pulmonary function. Participants being treated with aerosolized antibiotics were asked to inhale mucolytics first. Table 1 Clinical and demographic characteristics of participants with cystic fibrosis for inhaled sodium bicarbonate PI pancreatic insufficiency-assessment of pancreatic status was evaluated measuring fecal elastase in stool or fecal fat in 72-h stool collections in the routine diagnostic tests. Pancreatic enzyme replacement therapy was continued for cystic fibrosis (CF) patients with PI [24] . 
Clinical and Laboratory Markers

Elasticity, Viscosity, and pH of Sputum
Sputum was collected during all visits at intervals of 30 min over a 180-min period after the inhalation treatment as well as before and after the spirometry tests and Harvard step tests. A minimum sputum specimen of 3 mL was collected in a 15-mL sterile tube and frozen in dry ice for storage and transport. Rheological analysis evaluated specimen: (1) elasticity − G′ (stiffness); (2) viscosity − G″ (flow resistance); and (3) viscoelastic modulus − G* [15, 19] (see Electronic Supplementary Material (ESM) 1). The rheology analysis was performed using a Haake RheoStress 1 rheometer (Thermo Scientific ® , Waltham, MA, USA), according to the manufacturer's instructions. All rheology analyses were performed at the Department of Physics and Chemistry, Instituto de Química, Universidade Estadual de Campinas. The pH was measured concomitantly with the rheology in a ST2100 pH meter (OHAUS ® , Parsippany, NJ, USA) using a pH electrode (Digimed ® , São Paulo, Brazil) made specifically for fluids containing protein, fat, and/or creams. Room temperature was maintained at 23 °C. Specimens were equilibrated with room air and temperature, but not controlled for CO 2 tension.
Microbiology of Sputum
A semi-quantitative analysis was made of bacteria in the sputum specimens collected at the initial screening visit, V0, and at the final visit, V5. The bacterial load was classified as (1) +: light; (2) ++: moderate; and (3) +++: heavy. All specimens were assayed for the presence of mucoid and non-mucoid Pseudomonas aeruginosa and Staphylococcus aureus.
Spirometry
Spirometry was performed according to the American Thoracic Society and European Respiratory Society guidelines using a Koko ® Spirometer (nSpire Health, Longmont, CO, USA) [20] . At least three well-defined and reproducible maximum flow-volume loops were obtained: (1) before, (2) after administering the bronchodilator Salbutamol (C 13 H 21 NO 3 , 400 µg), and (3) after conducting the Harvard step-test exercise. The following parameters were measured: forced expiratory volume in 1 s (FEV 1 ), forced vital capacity (FVC), and forced expiratory flow rate between 25 and 75% of the FVC (FEF 25-75% ). The best result of three sequential exhalation efforts was recorded.
Peak Flow
Participants used a peak-flow meter according to the guidelines of the American Lung Association [21] . The best of three measurements taken during the clinic visits and at home (twice daily) were recorded.
Harvard Step Test
The step height was set at 30 cm (kikos™, São Paulo, Brazil). The following parameters were recorded: 
Cystic Fibrosis (CF) Quality-of-Life Questionnaire (CFQoLQ) and San Diego Questionnaire (SDQ) for Dyspnea
Participants answered the standard questionnaire at all visits [22, 23] .
Adverse Events
To assess the tolerability and possible side effects of inhaling aerosolized NaHCO 3 over time, participants completed a daily recall form (medications administered; visual analogue scale for dyspnea; cough activity; respiratory congestion, as well as other clinical indicators including pulmonary exacerbations, sinusitis, hemoptysis, malaise or lack of energy, weight loss, fever, absence from work/school. At all visits, the following were measured: heart rate, respiratory rate, peripheral oxygen saturation of hemoglobin (SpO 2 ), weight, arterial blood pressure, and body temperature. In addition, an automatic blood cell count (red blood cell, white blood cells, and platelets) as well as venous blood gas levels were obtained at the initial visit, V0, and the final visit, V5.
Statistical Analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences version 24.0 (IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Armonk, NY, USA). The statistical design is shown in ESM 1.
Results
Initially, 19 volunteer participants with CF, who were not using aerosolized hypertonic saline inhalation therapy, were enrolled. Seven of these 19 volunteers were excluded from the study due to complicating conditions: (1) insufficient sputum production to perform the rheology measures (n = 1), (2) poor adherence to the protocol (n = 1) (participant used less than 80% of the drug dose); (3) oxygen therapy required prior to beginning the intervention (n = 1) [oxygen therapy was prescribed by a physician at the screening visit, V0, and the trial investigator was informed], (4) insufficient time for weekly visits (n = 2), (5) pulmonary exacerbations at the onset of the study (n = 2) [during the clinical evaluation two physicians concluded the incidents observed as exacerbations were ongoing with prior bacterial colonization. Even though it seems unlikely, we cannot discard the possibility that the intervention was a contributing factor, and we note them as possible adverse events. Importantly, the exacerbation appeared during the first period of inhalation and was noted as a clinical finding during the first visit, V1. Consequently, both patients were excluded from the study and no data were collected from these patients]. All 12 participants who completed the protocol were more than 18 years of age and were diagnosed with bronchiectasis; five were female; nine were pancreatic insufficient. Their spirometry FEV 1 values were classified as mild (> 60%; n = 6), moderate (41-59%; n = 5), or severe (≤ 40%; n = 8) ( Table 1) . Four patients continued inhaling aerosolized dornase alpha as therapy during the protocol.
To assess adherence, the participants responded to a questionnaire concerning their routine healthcare. An additional questionnaire with subjective questions regarding fatigue, daily sputum characteristics, and symptoms associated with dyspnea were scored. Incomplete questionnaires delivered during the visits were interpreted as insufficient interest to participate in the study. Concomitantly, the drug supplied to the participant was dated with the correct day for use, and the participant was instructed to return all empty and full vials to the study personnel on each subsequent visit.
Pertaining directly to the safety and tolerability of inhaling aerosolized NaHCO 3 , no changes were observed in: complete blood count, venous blood gas, heart rate, respiratory rate, SpO 2 , body temperature, or the dyspnea questionnaire (data not shown; p ≥ 0.05). Participants reported no serious adverse events. One participant complained of a burning sensation on the lips, which was resolved by ingesting water during inhalation, and recommending exhaling outside the mouthpiece. Two participants reported cough during the first inhalation, which did not re-occur subsequently.
Rheology, Spirometry, Microbiology
Comparison of the rheology values (G′, G″, and G*) between visits and during the visits did not show significant differences (p > 0.05) (ESM 2). Spirometry and microbiology results did not differ during the intervention (Table 4 ; ESM 3).
pH
After NaHCO 3 was inhaled, the pH of the first specimen of sputum taken each day was the highest of all subsequent specimens and showed statistically higher values in visits V3 and V4 than at the screening visit (V0) (8.4%, p = 0.004 and 0.001) ( Table 2 ; Fig. 1 ). Furthermore, at all visits after inhalation of NaHCO 3 aerosol, the mean pH of samples collected between time zero and 180 min decreased with time to the pH of the screening sample at V0 (p < 0.05) ( Table 2) . Despite being an exploratory and underpowered analysis, an inverse correlation was observed between pH and rheology markers when all data were considered (G′ = − 0.241; G″ = − 0.287; G* = − 0.275) ( Table 5 ) and the mean value obtained at each visit (G′ = − 0.312; G″ = − 0.384; G* = − 0.336) (p < 0.001) (ESM 4). Oxygen consumption (p = 0.025), energy expenditure (p = 0.024), quality-of-life markers [treatment burden (p = 0.010); health perceptions (p = 0.011) and total score (p = 0.009)] showed improvement during the intervention period (Tables 2, 3 ). Other significant correlations were obtained with markers for: (1) G* versus peak flow, FEV 1 , quality of life (vitality, social, eating disturbances, and respiratory scores); (2) G′ versus peak flow, FVC, FEV 1 (before and after the Harvard step test), quality of life (vitality, social, eating disturbances, and respiratory scores); (3) G″ versus quality of life (vitality, social, eating disturbances, and respiratory scores); (4) pH versus VO 2 , vitality score in quality of life (ESM 4). Small correlations could be evidence of alterations in rheology (beside being a minimum change) with inhaled use of NaHCO 3 that minimally alters the sputum pH for a brief period.
Spearman correlations between the values for dyspnea, peak flow, Harvard step test, spirometry, and quality of life and between the values for spirometry and quality of life of participants with CF during the protocol with inhaled bicarbonate can be seen, respectively, in ESM 5 and ESM 6. All positive correlations were small, and more studies need to be carried out to confirm these exploratory findings (Tables 4, 5) .
No changes were observed in blood count, venous blood gas, respiratory rate, heart rate, SpO 2 , body temperature, or incidence of dyspnea.
Importantly, no adverse events associated with the study were observed.
Discussion
This in vivo clinical study assesses the safety, tolerability, and effects of NaHCO 3 inhalation in subjects with CF. The pH and rheological properties of sputum as well as clinical/laboratory data were evaluated before, during, and Table 2 Values for expectorated sputum pH, peak flow, and Harvard step test of participants with cystic fibrosis before (screening) and after inhaled bicarbonate protocols Visits: All visits occurred immediately after completing the indicated inhalation regimen. Each regime was conducted for a period of 2 weeks. Combined analysis-first line shows the arithmetic mean for the data collected during visits at 30-min intervals for 180 min. Second line shows mean for visits 1-4 c In the post-inhalation period, sputum pH collected during screening was significantly lower compared to visit 3 (p = 0.026) and visit 4 (p = 0.02). At visit 5, the pH value was significantly lower than the value observed at visits 2, 3, and 4 (p = 0.011, 0.050, 0.015, respectively) d At visit 3, the first collection had a higher pH value compared to all others-30 min (p = 0.001), 60 min (p = 0.002), 90 min (p = 0.008), 120 min (p = 0.034), 150 min (p = 0.015), 180 min (p = 0.021) e At visit 4, the first collection had a higher pH value when compared to later collections-30 min (p = 0.003), 60 min (p = 0.004), 90 min (p = 0.001), 120 min (p = 0.004), 150 min (p = 0.001), 180 min (p = 0.003) f No difference was observed between the all-pairwise test groups by the Bonferroni method g VO 2 was lower in the intervention period when compared to the post-intervention period (p = 0.030) h Work was higher after the intervention period when compared to the period during the intervention (p = 0.030) pH of sputum after interventions with inhaled aerosols of two concentrations (4.2% and 8.4%) of solutions of NaHCO 3 with a dose escalation every 2 weeks for eight consecutive weeks. The data show that inhaled NaHCO 3 acutely raised the pH of sputum, which correlated well with all rheological moduli (G′, G″, and G*). In addition, other markers, including quality of life and the Harvard step test, improved significantly during the study intervention period. NaHCO 3 is essential for proper expansion and maturation of mucin granules [8, 11, 16] . In addition, mucin granules are influenced by many factors, such as hydration, pH, solution ionic strength, composition, concentration, electrostatic interactions between mucins, size of polymers, degree of cross-linking, debris, etc. [25] .
In a study on the effect of mixing NaHCO 3 solution directly with the sputum of CF patients in vitro, Stigliani et al. [15] reported reductions in rheological moduli G′, G″, and G*. However, the present study evaluated native expectorated sputum. In the samples from the same participant and among the participants, quantitative/qualitative macroscopic variability was observed, particularly in the volume of expectorations. The large variability in properties between individual sputum specimens will likely require a much larger population to firmly establish statistically significant changes resulting from inhaled NaHCO 3 aerosols. Nonetheless, in the present small population, the results between screening V0 and after washout V5 often indicated a statistically significant change in sputum properties such as pH at visits V2-V4 that may be clinically important for future studies.
The variability of sputum rheology is multifactorial, including physicochemical aspects, and may be affected by: (1) repetitive voluntary cough, which may change the solid content and alter mucus hydration in the airways; (2) surface tension; (3) surface contact time with the respiratory airways; (4) adherence to bronchial wall [26] . The most direct method to obtain sputum may be bronchoscopy with bronchoalveolar lavage; however, due to ethical considerations and the probable change in properties of the mucus as a consequence of the saline wash to remove the native sputum, this method was not used [19] . The bicarbonate solution is hyperosmotic and may draw fluid into the airway surface liquids (ASL) as is thought to occur with hypertonic saline, thereby "thinning" the ASL and its contents. Again, like hypertonic saline, it may act as a minor irritant and stimulate airways secretions too.
Although native expectorated sputum was evaluated, the gel component of sputum in rheological analysis is critically important. Recent studies [27, 28] describe a positive correlation of the gel component with the G′, G″, and G* moduli. Here, liquids and saliva largely separated spontaneously from the gel component of the sputum when compressed between the rheometer plates supporting the presumption that measurements principally reflect gel (mucus) properties. Rheological differences in sputum from patients with CF, chronic obstructive pulmonary disease, and acute pulmonary infections have been reported [19] . During pulmonary exacerbations, elasticity and viscosity are increased, and return to basal levels only after antibiotic therapy along with normalization of pulmonary function [29] .
An important finding herein is that an increase in sputum pH immediately accompanies NaHCO 3 inhalation. Lower pH of ASL favors bacterial growth. A recent study in a porcine CF model found the growth of micro-organisms in CF was enhanced significantly in reduced extracellular fluid pH resulting from decreased secretion of HCO 3 − [13] . Presently, we are not able to establish that higher pH associated with the interventions here inhibited bacterial growth; further studies are needed for confirmation. (V5) no drug-wash-out period. In the post-inhalation period, sputum pH collected during screening was significantly lower compared to visit 3 (p = 0.026) and visit 4 (p = 0.02). At visit 5 (washout), the pH value was significantly lower than the values observed at visits 2, 3, and 4 (p = 0.011, 0.050, 0.015, respectively). Statistical analysis was performed by ANOVA with repeated measures by multivariate tests (Pillai's trace, Wilks' lambda, Hotelling's trace, and Roy's largest root), with post hoc pairwise analysis by the Bonferroni test. The covariance matrix of the transformed and orthonormalized dependent variable error was evaluated by Mauchly's sphericity test. All participants were included in the evaluation. Alpha = 0.05 Table 3 Quality-of-life scores from subjects with cystic fibrosis during the protocol with inhaled bicarbonate *Statistical analysis performed by Friedman's two-way analysis of variance by paired sample stations. In the comparison with the pairwise method between groups with significant p values (p values adjusted for multiple comparisons): treatment-the score was lower before intervention when compared to the post-intervention period (p = 0.018); health-in the simultaneous analysis for all groups, no significant association was observed; however, in grouped data, a lower score was obtained before the intervention compared to the post-intervention period (p = 0.043); digestive-no significant association in the analysis; Overall total in the simultaneous analysis for all groups the score was significantly lower before the intervention compared to the post-intervention period (p = 0.034). The analysis for the grouped data similarly was significantly different (p = 0.007). Significant p values are in bold. Alpha = 0.05 a Combined analysis gives the arithmetic mean for the data collected from all subjects during each separate visit, then the arithmetic mean of all visits after regimens one to four were calculated together b Visits: Each visit occurred after 2 weeks on each regime indicated. Visit 1: 4.2% NaHCO 3 aerosol was inhaled once a day. Visit 2: 4.2% NaHCO 3 , aerosol was inhaled twice daily; Visit 3: 8.4% NaHCO 3 , aerosol was inhaled once a day; Visit 4: 8.4% NaHCO 3 aerosol was inhaled twice daily. After last day of 8.4% inhalations, no NaHCO 3 was inhaled during the 15 days before the evaluation at Visit 5. Data presented as medians (25th percentile-75th percentile) In healthy subjects, the pH of ASL was reported to range from 6.85 to 7.65 [30, 31] , but in CF, the range was reported to be 4.5-8.5 [31] . In the present study, NaHCO 3 inhalation raised the sputum pH significantly in all visits and to ~ 7.9 in the last three visits, which is higher than the maximum value reported for healthy subjects (7.65). The duration of the raised pH effect of the inhalation (which required about 15-20 min to inhale nebulized the dose) was approximately 150 min. Therefore, increasing the frequency of NaHCO 3 inhalations should be tested (every 4-6 h dosing); considering that most patients are prescribed airway clearance therapy two to three times per day, more frequent bicarbonate dosing may be feasible, but a search for alternative formulations that might allow a longer duration of action seems justifiable. A corroborating increase in pH due to NaHCO 3 in vitro has been described [15] .
The most favorable pH for growth and maintenance of bacterial colonization/infection in CF lungs is uncertain.
However, it is commonly accepted that in CF a low volume of ASL and/or its acidity due to lack of HCO 3 − changes mucociliary clearance and favors pulmonary infection [1, [32] [33] [34] . Recent findings of acidity on the airway luminal epithelium in CF affirms the development of poor mucociliary clearance and infection [8, 13, 35, 36] . In contrast, others have reported that airway pH in CF is not different from that of healthy subjects [37, 38] . In short, bacteria decreased in 11 assays, increased in seven assays, and remained unchanged in 17 assays.
Using FEV 1 as a principal clinical marker, higher viscoelasticity of mucus appears to contribute to pulmonary obstruction and reduced lung function [39] . This marker was followed in multicenter studies of inhaled hypertonic saline and dornase alpha to demonstrate FEV 1 increased with these drugs [40] . Although the present study did not reach statistical significance, two participants had improved FEV 1 after inhaling NaHCO 3 (data not shown); thus, for a more compelling analysis of FEV 1 responses, a larger sample size and follow-up study, possibly for a longer duration of treatment, are required.
Quality of life is a marker widely used in intervention studies for new drugs as it provides personalized patient input [41, 42] . As a consequence of the results considered above, a cascade of events may occur that affect the quality of life. Lower pH changes the immune response in airways, and increases bacterial colonization favoring biofilm formation with a consequent increase in inflammation/infection, airway obstruction, and worsening of quality of life Table 4 Microbiological characterization of sputum from participants with cystic fibrosis before and after the intervention period with inhaled sodium bicarbonate A semi-quantitative analysis of bacterial content in the sputum specimens was performed at the initial screening visit (pre) and at the final visit 5 (post). The bacterial load was classified as: + light; ++ moderate; +++ heavy. The S. aureus load was reduced in five participants; mucoid P. aeruginosa was reduced in four participants, and non-mucoid P. aeruginosa was reduced in two participants. However, five participants and two participants showed an increased bacterial load with non-mucoid P. aeruginosa and mucoid P. aeruginosa, respectively. Overall, bacteria decreased in 11 assays, increased in seven and remained unchanged in 17 assays [43] [44] [45] . Of note, the highest rheology values (increased viscoelasticity) were associated with worsening dyspnea, but correlations were weak. Low tolerability to physical exercise is a common effect of CF, which increases with disease severity and is related to a higher mortality rate [46] . The Harvard step test is an accepted tool to evaluate tolerability to physical exercise [47] . Higher values of this measure related to a lower incidence of cardiopulmonary disease and better predisposition or physical activity [48, 49] . Here, the Harvard step test showed an improvement in oxygen consumption and energy expenditure after the intervention with inhaled NaHCO 3 ( Table 2 ). In spite of being an exploratory analysis, our data indicated an improvement in both oxygen consumption and energy expenditure that appeared to be related to the intervention and could be associated with a better capacity to perform daily life activities with inhaled NaHCO 3 .
In brief, as reported in Sect. 2, an exacerbation was observed during the first period of inhalation in two patients and was noted as a clinical finding during the first visit, V1. An incidence of exacerbations in patients with CF might be expected to be greater than two of 19 potential subjects in this timeframe. Thus, it seems reasonable that these events preceded the intervention and were not caused by it. Consequently, both patients were excluded from the analysis and no data were collected from these patients. It is important to note that no further incidence of exacerbations occurred at any time in any of the remaining participants during the 10 weeks of the study.
Study Limitations
The apparent limitations of this study include: (1) inadequate sample size to confirm or reject correlations and establish intervention effects. However, a recent study of 12 patients with CF showed that acute and longitudinal changes in lung function correlated with mucus rheology in spite of very heterogenous parameters among the patients [29] . (2) Suboptimal sputum separation (saliva, mucus gel, air) to perform precision rheological assays. (3) Lack of a placebo and/or active control group (e.g., hypertonic saline). (4) Short-term follow-up for a more robust identification of clinical markers such as lung function. (5) Older patients with more severe lung disease that may obscure lung function improvements, in view of likely irreversible damage to airways and lung parenchyma. (6) Alkalization of ASL may impede bacteria growth; therefore, we collected specimens for culture only after V5, the fifth and final visit (wash-out). It seems possible that sputum cultures at the end of V4 would have been more appropriate for evaluating acute versus longer term microbiological effects. (7) During the trial interventions we did not collect blood for complete blood counts or venous blood gas.
The study limitations might be reduced by: (1) increasing the sample size and follow-up time with the inclusion of more than one center. (2) Selecting participants without extremely severe disease; including younger participants with less severe airway pathology. (3) Further exploration for optimal intervention duration, dose concentration, and inhalation frequency for NaHCO 3 (dose-escalation study). (4) Evaluating mucins and inflammatory markers in fresh, native sputum at the time of collection.
Conclusion
This study documents that inhalation of aerosolized NaHCO 3 is safe and very well tolerated by CF participants. There were no significant adverse events associated with the interventions, even at the highest dosage of 5 mL saturated solution of NaHCO 3 (8.4%) inhaled twice daily. However, due to the small number of participants and inherently wide range in values of measured parameters, for example, sputum specimen (rheology/pH), spirometry, fitness, microbiology, and other variables in the population, the effects of the intervention merit further studies in a larger number of subjects to reveal and establish the potential therapeutic benefits that are suggested here. The apparent benefits of inhaled NaHCO 3 are due most likely to its effects on raising the pH of the ASL and on improving sputum rheology as a function of more fully expanded mucin and DNA macromolecules in the presence of higher concentrations of HCO 3 − in the ASL. These changes would enhance the respiratory immune defense and favor improved mucociliary clearance of the airways in maintaining improved airway hygiene.
In conclusion, even though most measured parameters did not achieve statistical significance, the means of the measurements of effects almost always remained constant or changed in the direction of presumed improvement, giving confidence that the treatment did not depress or impede normal function. The favorable changes observed in several parameters in this study may support inhalation of nebulized NaHCO 3 as a safe and well-tolerated therapeutic agent in the management of CF and possibly other obstructive lung diseases.
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